keyword
https://read.qxmd.com/read/38425181/genetic-determinants-of-thiazide-induced-hyperuricemia-hyperglycemia-and-urinary-electrolyte-disturbances-a-genome-wide-evaluation-of-the-uk-biobank
#1
JOURNAL ARTICLE
Innocent G Asiimwe, Lauren Walker, Reecha Sofat, Andrea L Jorgensen, Munir Pirmohamed
Thiazide diuretics, widely used in hypertension, cause a variety of adverse reactions, including hyperglycemia, hyperuricemia, and electrolyte abnormalities. In this study, we aimed to identify genetic variants that interact with thiazide-use to increase the risk of these adverse reactions. Using UK Biobank data, we first performed genomewide variance quantitative trait locus (vQTL) analysis of ~ 6.2 million SNPs on 95,493 unrelated hypertensive White British participants (24,313 on self-reported bendroflumethiazide treatment at recruitment) for 2 blood (glucose and urate) and 2 urine (potassium and sodium) biomarkers...
February 29, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38115960/prevalence-of-chronic-pain-or-analgesic-use-in-children-and-young-people-and-its-long-term-impact-on-substance-misuse-mental-illness-and-prescription-opioid-use-a-retrospective-longitudinal-cohort-study
#2
JOURNAL ARTICLE
Andrew Lambarth, Michail Katsoulis, Chengsheng Ju, Alasdair Warwick, Rohan Takhar, Caroline Dale, David Prieto-Merino, Andrew Morris, Debajit Sen, Li Wei, Reecha Sofat
BACKGROUND: Epidemiological studies suggest chronic and recurrent pain affects around a quarter of children, while 8% report intense and frequent pain. The long-term implications of chronic pain in childhood are uncertain. Using electronic health records (EHRs) we used both disease codes and medicines prescription records to investigate the scale of chronic pain and long-term analgesic use in children and young people (CYP), and if chronic pain and/or use of analgesic medicines at an early age is associated with substance misuse, use of prescription opioids, and poor mental health in adulthood...
December 2023: The Lancet regional health. Europe
https://read.qxmd.com/read/37974394/drug-induced-orthostatic-hypotension-cluster-analysis-of-co-prescription-patterns-in-older-people-in-uk-primary-care
#3
JOURNAL ARTICLE
Cini Bhanu, Irene Petersen, Mine Orlu, Daniel Davis, Reecha Sofat, Juan Carlos Bazo-Alvarez, Kate Walters
PURPOSE: Over 250 medications are reported to cause orthostatic hypotension, associated with serious adverse outcomes in older adults. Studies suggest a harmful cumulative risk of orthostatic hypotension with multiple medication use. However, there is limited evidence on the potential for harm in practice, particularly which drugs is co-prescribed and may increase risk of orthostatic hypotension. METHODS: Retrospective cohort study and cluster analysis using general practice data from IQVIA Medical Research Data (IMRD) in patients aged ≥50 contributing data between 1 January 2018 and 31 December 2018...
January 2024: Pharmacoepidemiology and Drug Safety
https://read.qxmd.com/read/37949472/ethnic-disparities-in-progression-rates-for-sight-threatening-diabetic-retinopathy-in-diabetic-eye-screening-a-population-based-retrospective-cohort-study
#4
JOURNAL ARTICLE
Abraham Olvera-Barrios, Christopher G Owen, John Anderson, Alasdair N Warwick, Ryan Chambers, Louis Bolter, Yue Wu, Roshan Welikala, Jiri Fajtl, Sarah A Barman, Paolo Remagnino, Emily Y Chew, Frederick L Ferris, Aroon D Hingorani, Reecha Sofat, Aaron Y Lee, Catherine Egan, Adnan Tufail, Alicja R Rudnicka
INTRODUCTION: The English Diabetic Eye Screening Programme (DESP) offers people living with diabetes (PLD) annual eye screening. We examined incidence and determinants of sight-threatening diabetic retinopathy (STDR) in a sociodemographically diverse multi-ethnic population. RESEARCH DESIGN AND METHODS: North East London DESP cohort data (January 2012 to December 2021) with 137 591 PLD with no retinopathy, or non-STDR at baseline in one/both eyes, were used to calculate STDR incidence rates by sociodemographic factors, diabetes type, and duration...
November 2023: BMJ Open Diabetes Research & Care
https://read.qxmd.com/read/37875374/two-year-recall-for-people-with-no-diabetic-retinopathy-a-multi-ethnic-population-based-retrospective-cohort-study-using-real-world-data-to-quantify-the-effect
#5
JOURNAL ARTICLE
Abraham Olvera-Barrios, Alicja R Rudnicka, John Anderson, Louis Bolter, Ryan Chambers, Alasdair N Warwick, Roshan Welikala, Jiri Fajtl, Sarah Barman, Paolo Remgnino, Yue Wu, Aaron Y Lee, Emily Y Chew, Frederick L Ferris, Aroon Hingorani, Reecha Sofat, Catherine A Egan, Adnan Tufail, Christopher G Owen
BACKGROUND/AIMS: The English Diabetic Eye Screening Programme (DESP) offers people living with diabetes (PLD) annual screening. Less frequent screening has been advocated among PLD without diabetic retinopathy (DR), but evidence for each ethnic group is limited. We examined the potential effect of biennial versus annual screening on the detection of sight-threatening diabetic retinopathy (STDR) and proliferative diabetic retinopathy (PDR) among PLD without DR from a large urban multi-ethnic English DESP...
November 22, 2023: British Journal of Ophthalmology
https://read.qxmd.com/read/37859783/performance-of-polygenic-risk-scores-in-screening-prediction-and-risk-stratification-secondary-analysis-of-data-in-the-polygenic-score-catalog
#6
JOURNAL ARTICLE
Aroon D Hingorani, Jasmine Gratton, Chris Finan, A Floriaan Schmidt, Riyaz Patel, Reecha Sofat, Valerie Kuan, Claudia Langenberg, Harry Hemingway, Joan K Morris, Nicholas J Wald
OBJECTIVE: To clarify the performance of polygenic risk scores in population screening, individual risk prediction, and population risk stratification. DESIGN: Secondary analysis of data in the Polygenic Score Catalog. SETTING: Polygenic Score Catalog, April 2022. Secondary analysis of 3915 performance metric estimates for 926 polygenic risk scores for 310 diseases to generate estimates of performance in population screening, individual risk, and population risk stratification...
2023: BMJ Med
https://read.qxmd.com/read/37549998/device-based-measurement-of-physical-activity-in-cardiovascular-healthcare-possibilities-and-challenges
#7
EDITORIAL
Timothy James Chico, Emmanuel Stamatakis, Fabio Ciravegna, Jessilyn Dunn, Simon Redwood, Rasha Al-Lamee, Reecha Sofat, Jason Gill
No abstract text is available yet for this article.
October 2023: British Journal of Sports Medicine
https://read.qxmd.com/read/37543047/antipsychotic-drug-prescribing-and-mortality-in-people-with-dementia-before-and-during-the-covid-19-pandemic-a-retrospective-cohort-study-in-wales-uk
#8
JOURNAL ARTICLE
Christian Schnier, Aoife McCarthy, Daniel R Morales, Ashley Akbari, Reecha Sofat, Caroline Dale, Rohan Takhar, Mamas A Mamas, Kamlesh Khunti, Francesco Zaccardi, Cathie Lm Sudlow, Tim Wilkinson
BACKGROUND: Concerns have been raised that antipsychotic drug prescribing, which has been associated with increased mortality in people with dementia, might have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of SARS-CoV-2. We used multisource, routinely collected health-care data from Wales, UK to investigate prescribing and mortality variations in people with dementia before and during the COVID-19 pandemic. METHODS: In this retrospective cohort study, we used individual-level, anonymised, population-scale linked health data to identify adults aged 60 years and older with a diagnosis of dementia in Wales, UK...
August 2023: The Lancet. Healthy longevity
https://read.qxmd.com/read/37480157/effectiveness-of-biosimilar-adoption-within-a-uk-tertiary-hospital-six-years-follow-up
#9
JOURNAL ARTICLE
Andrew Barron, Jennifer Chung, Robin E Ferner, Maria Leandro, Saloni Maru, Andrew Scourfield, Robert Urquhart, Reecha Sofat
Health systems encourage switching from originators to biosimilars as biosimilars are more cost-effective. The speed and completeness of biosimilar adoption is a measure of efficiency. We describe the approach to biosimilar adoption at a single hospital and compare its efficiency against the English average. We additionally follow up patients who reverted to a previously used biologic, having switched to a biosimilar, to establish whether they benefitted from re-establishing prior treatment. The approach we describe resulted in a faster and more complete switch to biosimilars, which saved an additional £380,000 on drug costs in 2021/22...
July 21, 2023: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/37313748/how-to-assess-pharmacogenomic-tests-for-implementation-in-the-nhs-in-england
#10
JOURNAL ARTICLE
Sonali Sanghvi, Robin E Ferner, Andrew Scourfield, Robert Urquhart, Sejal Amin, Aroon D Hingorani, Reecha Sofat
No abstract text is available yet for this article.
June 14, 2023: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/36658423/the-impact-of-the-covid-19-pandemic-on-cardiovascular-disease-prevention-and-management
#11
JOURNAL ARTICLE
Caroline E Dale, Rohan Takhar, Raymond Carragher, Michail Katsoulis, Fatemeh Torabi, Stephen Duffield, Seamus Kent, Tanja Mueller, Amanj Kurdi, Thu Nguyen Le Anh, Stuart McTaggart, Hoda Abbasizanjani, Sam Hollings, Andrew Scourfield, Ronan A Lyons, Rowena Griffiths, Jane Lyons, Gareth Davies, Daniel Harris, Alex Handy, Mehrdad A Mizani, Christopher Tomlinson, Johan H Thygesen, Mark Ashworth, Spiros Denaxas, Amitava Banerjee, Jonathan A C Sterne, Paul Brown, Ian Bullard, Rouven Priedon, Mamas A Mamas, Ann Slee, Paula Lorgelly, Munir Pirmohamed, Kamlesh Khunti, Andrew D Morris, Cathie Sudlow, Ashley Akbari, Marion Bennie, Naveed Sattar, Reecha Sofat
How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management of cardiovascular disease (CVD) is not fully understood. In this study, we used medication data as a proxy for CVD management using routinely collected, de-identified, individual-level data comprising 1.32 billion records of community-dispensed CVD medications from England, Scotland and Wales between April 2018 and July 2021. Here we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes compared to the previous year, for several CVD-related indications, focusing on hypertension, hypercholesterolemia and diabetes...
January 2023: Nature Medicine
https://read.qxmd.com/read/36460578/identifying-and-visualising-multimorbidity-and-comorbidity-patterns-in-patients-in-the-english-national-health-service-a-population-based-study
#12
JOURNAL ARTICLE
Valerie Kuan, Spiros Denaxas, Praveetha Patalay, Dorothea Nitsch, Rohini Mathur, Arturo Gonzalez-Izquierdo, Reecha Sofat, Linda Partridge, Amanda Roberts, Ian C K Wong, Melanie Hingorani, Nishi Chaturvedi, Harry Hemingway, Aroon D Hingorani
BACKGROUND: Globally, there is a paucity of multimorbidity and comorbidity data, especially for minority ethnic groups and younger people. We estimated the frequency of common disease combinations and identified non-random disease associations for all ages in a multiethnic population. METHODS: In this population-based study, we examined multimorbidity and comorbidity patterns stratified by ethnicity or race, sex, and age for 308 health conditions using electronic health records from individuals included on the Clinical Practice Research Datalink linked with the Hospital Episode Statistics admitted patient care dataset in England...
November 29, 2022: The Lancet. Digital health
https://read.qxmd.com/read/36419802/the-urgent-need-to-move-upstream-in-caring-for-people-with-rheumatic-and-musculoskeletal-diseases
#13
EDITORIAL
Aicha Bouraoui, Megan Rutter, Luke Williamson, Corinne Fisher, Reecha Sofat, Debajit Sen
No abstract text is available yet for this article.
2022: Rheumatology Advances in Practice
https://read.qxmd.com/read/35690576/covid-19-trajectories-among-57-million-adults-in-england-a-cohort-study-using-electronic-health-records
#14
JOURNAL ARTICLE
Johan H Thygesen, Christopher Tomlinson, Sam Hollings, Mehrdad A Mizani, Alex Handy, Ashley Akbari, Amitava Banerjee, Jennifer Cooper, Alvina G Lai, Kezhi Li, Bilal A Mateen, Naveed Sattar, Reecha Sofat, Ana Torralbo, Honghan Wu, Angela Wood, Jonathan A C Sterne, Christina Pagel, William N Whiteley, Cathie Sudlow, Harry Hemingway, Spiros Denaxas
BACKGROUND: Updatable estimates of COVID-19 onset, progression, and trajectories underpin pandemic mitigation efforts. To identify and characterise disease trajectories, we aimed to define and validate ten COVID-19 phenotypes from nationwide linked electronic health records (EHR) using an extensible framework. METHODS: In this cohort study, we used eight linked National Health Service (NHS) datasets for people in England alive on Jan 23, 2020. Data on COVID-19 testing, vaccination, primary and secondary care records, and death registrations were collected until Nov 30, 2021...
July 2022: The Lancet. Digital health
https://read.qxmd.com/read/35060169/pharmacogenomic-alerts-developing-guidance-for-use-by-healthcare-professionals
#15
JOURNAL ARTICLE
John-Paul L Carter, James Critchlow, Sarah Jackson, Sonali Sanghvi, Helene Feger, Afzal Chaudhry, Lorraine Foley, Reecha Sofat
AIMS: For diseases with a genetic cause, genomics can deliver improved diagnostics and facilitate access to targeted treatments. Drug pharmacodynamics and pharmacokinetics are often dependent on genetic variation underlying these processes. As pharmacogenomics comes of age, it may be the first way in which genomics is utilised at a population level. Still required is guidance and standards of how genomic information can be communicated within the health record, and how clinicians should be alerted to variation impacting the use of medicines...
July 2022: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/35028631/the-importance-of-blood-pressure-thresholds-versus-predicted-cardiovascular-risk-on-subsequent-rates-of-cardiovascular-disease-a-cohort-study-in-english-primary-care
#16
JOURNAL ARTICLE
Emily Herrett, Helen Strongman, Sarah Gadd, Laurie Tomlinson, Dorothea Nitsch, Krishnan Bhaskaran, Elizabeth Williamson, Tjeerd van Staa, Reecha Sofat, Adam Timmis, Susan Wells, Liam Smeeth, Rod Jackson
BACKGROUND: For five decades, blood pressure lowering treatment has been recommended for patients with hypertension (currently defined as blood pressure of ≥140/90 mm Hg). In the past 20 years, guidelines for treatment began incorporating predicted absolute cardiovascular disease risk (predicted risk) and reducing blood pressure thresholds. The blood pressure threshold at which to start treatment has become a secondary consideration in some countries. We aimed to provide descriptive data to assess the relative importance of blood pressure thresholds versus predicted risk on the subsequent rate of cardiovascular disease to inform treatment decisions...
January 2022: The Lancet. Healthy longevity
https://read.qxmd.com/read/34734970/association-of-smoking-alcohol-consumption-blood-pressure-body-mass-index-and-glycemic-risk-factors-with-age-related-macular-degeneration-a-mendelian-randomization-study
#17
COMMENT
Valerie Kuan, Alasdair Warwick, Aroon Hingorani, Adnan Tufail, Valentina Cipriani, Stephen Burgess, Reecha Sofat
IMPORTANCE: Advanced age-related macular degeneration (AMD) is a leading cause of blindness in Western countries. Causal, modifiable risk factors need to be identified to develop preventive measures for advanced AMD. OBJECTIVE: To assess whether smoking, alcohol consumption, blood pressure, body mass index, and glycemic traits are associated with increased risk of advanced AMD. DESIGN, SETTING, PARTICIPANTS: This study used 2-sample mendelian randomization...
December 1, 2021: JAMA Ophthalmology
https://read.qxmd.com/read/34675202/validation-of-lipid-related-therapeutic-targets-for-coronary-heart-disease-prevention-using-human-genetics
#18
JOURNAL ARTICLE
María Gordillo-Marañón, Magdalena Zwierzyna, Pimphen Charoen, Fotios Drenos, Sandesh Chopade, Tina Shah, Jorgen Engmann, Nishi Chaturvedi, Olia Papacosta, Goya Wannamethee, Andrew Wong, Reecha Sofat, Mika Kivimaki, Jackie F Price, Alun D Hughes, Tom R Gaunt, Deborah A Lawlor, Anna Gaulton, Aroon D Hingorani, Amand F Schmidt, Chris Finan
Drug target Mendelian randomization (MR) studies use DNA sequence variants in or near a gene encoding a drug target, that alter the target's expression or function, as a tool to anticipate the effect of drug action on the same target. Here we apply MR to prioritize drug targets for their causal relevance for coronary heart disease (CHD). The targets are further prioritized using independent replication, co-localization, protein expression profiles and data from the British National Formulary and clinicaltrials...
October 21, 2021: Nature Communications
https://read.qxmd.com/read/34641870/an-informatics-consult-approach-for-generating-clinical-evidence-for-treatment-decisions
#19
REVIEW
Alvina G Lai, Wai Hoong Chang, Constantinos A Parisinos, Michail Katsoulis, Ruth M Blackburn, Anoop D Shah, Vincent Nguyen, Spiros Denaxas, George Davey Smith, Tom R Gaunt, Krishnarajah Nirantharakumar, Murray P Cox, Donall Forde, Folkert W Asselbergs, Steve Harris, Sylvia Richardson, Reecha Sofat, Richard J B Dobson, Aroon Hingorani, Riyaz Patel, Jonathan Sterne, Amitava Banerjee, Alastair K Denniston, Simon Ball, Neil J Sebire, Nigam H Shah, Graham R Foster, Bryan Williams, Harry Hemingway
BACKGROUND: An Informatics Consult has been proposed in which clinicians request novel evidence from large scale health data resources, tailored to the treatment of a specific patient. However, the availability of such consultations is lacking. We seek to provide an Informatics Consult for a situation where a treatment indication and contraindication coexist in the same patient, i.e., anti-coagulation use for stroke prevention in a patient with both atrial fibrillation (AF) and liver cirrhosis...
October 12, 2021: BMC Medical Informatics and Decision Making
https://read.qxmd.com/read/34561430/cholesteryl-ester-transfer-protein-cetp-as-a-drug-target-for-cardiovascular-disease
#20
JOURNAL ARTICLE
Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, Christopher J O'Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan
Development of cholesteryl ester transfer protein (CETP) inhibitors for coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and drug target Mendelian randomization of CETP protein concentration, comparing this to Mendelian randomization of proprotein convertase subtilisin/kexin type 9 (PCSK9). We show that previous failures of CETP inhibitors are likely compound related, as illustrated by significant degrees of between-compound heterogeneity in effects on lipids, blood pressure, and clinical outcomes observed in trials...
September 24, 2021: Nature Communications
keyword
keyword
108100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.